Experimental therapy with 9-[2-(Phosphonomethoxy)ethyl]-2, 6-diaminopurine (PMEDAP): Origin of resistance

Autor:	Zapotocky, M., Hanzalova, J., Starkova, J., Votruba, I., Holy, A., Berta Otová
Předmět:	Male Transcriptional Activation Lymphoma Adenine Antineoplastic Agents Organ Size Rats Gene Expression Regulation Neoplastic Rats Sprague-Dawley Drug Resistance Neoplasm Cell Line Tumor Animals Humans Multidrug Resistance-Associated Proteins Neoplasm Transplantation
Zdroj:	Scopus-Elsevier ResearcherID Europe PubMed Central
Popis:	The role of MRP4 and MRP5 transporters in the acyclic nucleoside phosphonate PMEDAP efflux was studied in vitro (CCRF-CEM cells) and in vivo (spontaneous transplantable T-cell lymphoma of SD/Cub inbred rats). The increased resistance against the cytostatic agent PMEDAP during longterm treatment was found to be associated with overexpression of MRP4 and MRP5 genes. The course of both gene activation differs significantly. While the MRP5 function is important in the onset of PMEDAP resistance, the intensity of the relative MRP4 gene expression increases rather continuously. Our data indicate cooperative acting of both MRP4 and MRP5 genes during the PMEDAP resistance development.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::37ed511d47e67d87fa27eceed228877d http://www.scopus.com/inward/record.url?eid=2-s2.0-34250882212&partnerID=MN8TOARS Zobrazit plný text záznamu